| Symbol | BBIO |
|---|---|
| Name | BRIDGEBIO PHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 421 KIPLING STREET, PALO ALTO, California, 94301, United States |
| Telephone | +1 650 391-9740 |
| Fax | — |
| — | |
| Website | https://www.bridgebio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001743881 |
| Description | BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology. Additional info from NASDAQ: |
2026-07-24 18:20
New Form S-3ASR - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 0001140361-26-029624 <b>Size:</b> 959 KB
Read more
2026-07-24 18:17
New Form S-8 - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 0001140361-26-029623 <b>Size:</b> 206 KB
Read more
2026-07-02 20:23
(99% Positive) BRIDGEBIO PHARMA, INC. (BBIO) Announces Business Combination
Read more
2026-07-02 11:30
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
Read more
2026-07-02 06:35
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
Read more
2026-07-01 11:30
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
Read more
2026-07-01 06:37
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07398950 | Prospective Evaluation of Artificial Intelligence-enabled Screening for Transth… | — | ATTR Amyloidosis With Cardiomyopathy | Not_Yet_Recruiting | 2026-07-15 | 2027-06-01 | ClinicalTrials.gov |
| NCT07695701 | Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis | Phase4 | Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) | Not_Yet_Recruiting | 2026-07-01 | 2030-11-01 | ClinicalTrials.gov |
| NCT07393373 | Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypocho… | Phase2 | Hypochondroplasia | Enrolling_By_Invitation | 2026-04-23 | 2036-05-31 | ClinicalTrials.gov |
| NCT07080385 | Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants W… | Phase2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Recruiting | 2026-01-30 | 2030-12-01 | ClinicalTrials.gov |
| NCT07169279 | Interventional Study of Infigratinib in Children < 3 Years Old With Achondropla… | Phase2 | Achondroplasia | Recruiting | 2025-11-19 | 2032-03-01 | ClinicalTrials.gov |
| NCT07116473 | To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants… | Phase3 | Amyloidosis in Transthyretin (TTR) | Not_Yet_Recruiting | 2025-11-01 | 2037-12-01 | ClinicalTrials.gov |
| NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) … | Phase3 | Amyloidosis | Recruiting | 2025-05-12 | 2032-12-01 | ClinicalTrials.gov |
| NCT06873035 | An Interventional Study of Infigratinib in Children With Hypochondroplasia | Phase2 | Hypochondroplasia | Enrolling_By_Invitation | 2025-04-22 | 2027-01-01 | ClinicalTrials.gov |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | Phase1 | Non-Small Cell Lung Cancer | Recruiting | 2025-03-31 | 2029-09-01 | ClinicalTrials.gov |
| NCT07062848 | An Observational Study Using Artificial Intelligence (AI) Algorithms on Electro… | — | Transthyretin (TTR) Amyloid Cardiomyopathy | Active_Not_Recruiting | 2025-01-24 | 2027-01-01 | ClinicalTrials.gov |
| NCT06625775 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Phase1 | Solid Tumor, Adult | Recruiting | 2024-10-29 | 2028-11-01 | ClinicalTrials.gov |
| NCT06410976 | Prospective Clinical Assessment Study in Children With Hypochondroplasia | — | Hypochondroplasia | Recruiting | 2024-06-05 | 2026-10-01 | ClinicalTrials.gov |
| NCT06469372 | Cardiac Amyloidosis Discovery Trial | Na | Cardiac Amyloidosis | Completed | 2024-05-28 | 2025-08-01 | ClinicalTrials.gov |
| NCT06343402 | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lun… | Phase1 | Non-small Cell Lung Cancer | Recruiting | 2024-05-22 | 2031-09-01 | ClinicalTrials.gov |
| NCT06164951 | A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Ado… | Phase3 | Achondroplasia | Completed | 2023-11-10 | 2025-12-18 | ClinicalTrials.gov |
| NCT05735015 | PTH-independent Effects of Encaleret | Phase2 | Post-Surgical Hypoparathyroidism | Completed | 2023-09-01 | 2025-08-12 | ClinicalTrials.gov |
| NCT05680818 | Efficacy and Safety of Encaleret Compared to Standard of Care in Participants W… | Phase3 | Autosomal Dominant Hypocalcemia (ADH) | Active_Not_Recruiting | 2023-01-06 | 2029-08-01 | ClinicalTrials.gov |
| NCT05375084 | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced … | Phase1 | Non Small Cell Lung Cancer | Terminated | 2022-10-20 | 2024-07-15 | ClinicalTrials.gov |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced … | Phase1 | Solid Tumor, Adult | Terminated | 2022-07-06 | 2024-08-22 | ClinicalTrials.gov |
| NCT05227287 | ADH1 and ADH2 Disease Monitoring Study (DMS) | — | Autosomal Dominant Hypocalcemia | Active_Not_Recruiting | 2022-01-20 | 2028-12-01 | ClinicalTrials.gov |
| NCT04972253 | Phase I BLASST-3 Trial | Phase1 | Bladder Transitional Cell Carcinoma | Withdrawn | 2021-12-23 | 2023-12-01 | ClinicalTrials.gov |
| NCT05145010 | Extension Study of Infigratinib in Children With Achondroplasia (ACH) | Phase2 | Achondroplasia | Enrolling_By_Invitation | 2021-12-06 | 2032-02-01 | ClinicalTrials.gov |
| NCT05143190 | Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bu… | Phase2 | Recessive Dystrophic Epidermolysis Bullosa | Completed | 2021-12-02 | 2022-08-09 | ClinicalTrials.gov |
| NCT04988386 | Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants | Phase3 | Amyloid Cardiomyopathy, Transthyretin-Related | Active_Not_Recruiting | 2021-10-27 | 2028-05-15 | ClinicalTrials.gov |
| NCT04882735 | Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid… | Phase3 | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Withdrawn | 2021-09-08 | 2026-10-01 | ClinicalTrials.gov |
| NCT04876924 | A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers | Phase1 | Healthy | Completed | 2021-04-29 | 2022-02-27 | ClinicalTrials.gov |
| NCT04769479 | A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Rel… | Phase1 | Amyloidosis | Completed | 2021-03-28 | 2021-09-03 | ClinicalTrials.gov |
| NCT04836494 | A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability… | Phase1 | Healthy Volunteers | Terminated | 2021-03-25 | 2023-11-20 | ClinicalTrials.gov |
| NCT04622046 | A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM | Phase3 | Symptomatic Transthyretin Amyloid Cardiomyopathy | Completed | 2020-11-13 | 2025-08-21 | ClinicalTrials.gov |
| NCT04528836 | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced So… | Phase1 | Tumor, Solid | Terminated | 2020-11-12 | 2024-07-30 | ClinicalTrials.gov |
| NCT04418024 | Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneuropha… | Phase3 | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Withdrawn | 2020-10-21 | 2024-04-30 | ClinicalTrials.gov |
| NCT04504331 | Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positiv… | Phase1 | Breast Cancer | Terminated | 2020-10-13 | 2021-10-22 | ClinicalTrials.gov |
| NCT05577819 | Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF | Na | Transthyretin Amyloidosis | Recruiting | 2020-10-02 | 2026-12-31 | ClinicalTrials.gov |
| NCT04409145 | First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations… | Phase1 | Venous Malformation | Terminated | 2020-10-01 | 2022-04-13 | ClinicalTrials.gov |
| NCT04581629 | Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal … | Phase2 | Autosomal Dominant Hypocalcemia (ADH) | Completed | 2020-09-20 | 2023-09-07 | ClinicalTrials.gov |
| NCT04424966 | Infigratinib in Recurrent High-Grade Glioma Patients | Early_Phase1 | Glioma | Terminated | 2020-07-21 | 2024-02-19 | ClinicalTrials.gov |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urotheli… | Phase3 | Upper Tract Urothelial Carcinomas | Terminated | 2020-03-11 | 2023-02-28 | ClinicalTrials.gov |
| NCT04265651 | Study of Infigratinib in Children With Achondroplasia | Phase2 | Achondroplasia | Completed | 2020-03-10 | 2024-10-21 | ClinicalTrials.gov |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma Wi… | Phase3 | Advanced Cholangiocarcinoma | Terminated | 2019-12-27 | 2023-03-02 | ClinicalTrials.gov |
| NCT04035811 | Prospective Clinical Assessment Study in Children With Achondroplasia (ACH) | — | Achondroplasia | Completed | 2019-08-12 | 2025-08-27 | ClinicalTrials.gov |
| NCT03860935 | Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopat… | Phase3 | Amyloidosis | Completed | 2019-03-19 | 2023-05-11 | ClinicalTrials.gov |
| NCT03458130 | Study of AG10 in Amyloid Cardiomyopathy | Phase2 | Familial ATTR-CM (ATTRm-CM, or FAC) | Completed | 2018-04-27 | 2018-10-05 | ClinicalTrials.gov |
| NCT03294707 | Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK… | Phase1 | Amyloid Cardiomyopathy, Transthyretin-Related | Completed | 2017-09-11 | 2018-05-18 | ClinicalTrials.gov |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarci… | Phase2 | Advanced Cholangiocarcinoma | Terminated | 2014-07-23 | 2022-02-07 | ClinicalTrials.gov |
Total clinical trials: 44
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ATTR-CM AI-ECG and AI-Echo Model | Other | Preclinical | ATTR Amyloidosis With Cardiomyopathy | NOT_YET_RECRUITING | NCT07398950 |
| infigratinib 0.25 mg/kg/day | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT06873035 |
| infigratinib 0.128 mg/kg/day | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT06873035 |
| Acoramidis (AG10) oral tablet | Other | Phase PHASE4 | Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) | NOT_YET_RECRUITING | NCT07695701 |
| Placebo oral tablet | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Acoramidis | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| FOLFOX | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Ribociclib | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Fulvestrant | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Trastuzumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| BBO-10203 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as a single dose of minitablets for oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Standard of Care | Other | Phase PHASE3 | Autosomal Dominant Hypocalcemia (ADH) | ACTIVE_NOT_RECRUITING | NCT05680818 |
| Encaleret | Other | Phase PHASE3 | Autosomal Dominant Hypocalcemia (ADH) | ACTIVE_NOT_RECRUITING | NCT05680818 |
| ALXN2060 | Other | Phase PHASE3 | Symptomatic Transthyretin Amyloid Cardiomyopathy | COMPLETED | NCT04622046 |
| Nab-paclitaxel | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Gemcitabine | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| mFOLFIRINOX | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| BBO-10203 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| mFOLFOX6 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Cetuximab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Pemetrexed | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Platinum chemotherapy (cisplatin or carboplatin) | Drug | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Pembrolizumab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| BBO-11818 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Placebo oral tablet | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Acoramidis | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as a single dose of minitablets for oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as a single dose of minitablets for oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Placebo oral tablet | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Acoramidis | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as a single dose of minitablets for oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Placebo oral tablet | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Acoramidis | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as a single dose of minitablets for oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Placebo oral tablet | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Acoramidis | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as a single dose of minitablets for oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Placebo oral tablet | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Acoramidis | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as a single dose of minitablets for oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Placebo oral tablet | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Acoramidis | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| sotorasib | Other | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT05480865 |
| BBP-398 | Other | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT05480865 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04876924 |
| BBP-711 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04876924 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04876924 |
| BBP-711 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04876924 |
| VT30 | Other | Phase PHASE1 | Venous Malformation | TERMINATED | NCT04409145 |
| VT30 | Other | Phase PHASE1 | Venous Malformation | TERMINATED | NCT04409145 |
| Infigratinib | Other | Phase PHASE1 | Bladder Transitional Cell Carcinoma | WITHDRAWN | NCT04972253 |
| Infigratinib | Other | Phase PHASE1 | Bladder Transitional Cell Carcinoma | WITHDRAWN | NCT04972253 |
| Placebo Oral Tablet | Other | Phase PHASE2 | Familial ATTR-CM (ATTRm-CM, or FAC) | COMPLETED | NCT03458130 |
| AG10 | Other | Phase PHASE2 | Familial ATTR-CM (ATTRm-CM, or FAC) | COMPLETED | NCT03458130 |
| Placebo Oral Tablet | Other | Phase PHASE2 | Familial ATTR-CM (ATTRm-CM, or FAC) | COMPLETED | NCT03458130 |
| AG10 | Other | Phase PHASE2 | Familial ATTR-CM (ATTRm-CM, or FAC) | COMPLETED | NCT03458130 |
| PTR-01 | Other | Phase PHASE2 | Recessive Dystrophic Epidermolysis Bullosa | COMPLETED | NCT05143190 |
| PTR-01 | Other | Phase PHASE2 | Recessive Dystrophic Epidermolysis Bullosa | COMPLETED | NCT05143190 |
| BGJ398 (infigratinib) | Other | Phase PHASE2 | Advanced Cholangiocarcinoma | TERMINATED | NCT02150967 |
| BGJ398 (infigratinib) | Other | Phase PHASE2 | Advanced Cholangiocarcinoma | TERMINATED | NCT02150967 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04836494 |
| BBP-671 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04836494 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04836494 |
| BBP-671 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04836494 |
| Placebo | Other | Phase PHASE3 | Upper Tract Urothelial Carcinomas | TERMINATED | NCT04197986 |
| Infigratinib | Other | Phase PHASE3 | Upper Tract Urothelial Carcinomas | TERMINATED | NCT04197986 |
| Placebo | Other | Phase PHASE3 | Upper Tract Urothelial Carcinomas | TERMINATED | NCT04197986 |
| Infigratinib | Other | Phase PHASE3 | Upper Tract Urothelial Carcinomas | TERMINATED | NCT04197986 |
| Cisplatin | Other | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| Gemcitabine | Other | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| BGJ398 | Other | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| Cisplatin | Other | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| Gemcitabine | Other | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| BGJ398 | Other | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| Cisplatin | Other | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| Gemcitabine | Other | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| BGJ398 | Other | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| Placebo Oral Tablet | Other | Phase PHASE3 | Amyloidosis | COMPLETED | NCT03860935 |
| acoramidis | Other | Phase PHASE3 | Amyloidosis | COMPLETED | NCT03860935 |
| Placebo Oral Tablet | Other | Phase PHASE3 | Amyloidosis | COMPLETED | NCT03860935 |
| acoramidis | Other | Phase PHASE3 | Amyloidosis | COMPLETED | NCT03860935 |
| Acoramidis | Other | Phase PHASE3 | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | WITHDRAWN | NCT04882735 |
| Acoramidis | Other | Phase PHASE3 | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | WITHDRAWN | NCT04882735 |
| acoramidis | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT04769479 |
| acoramidis | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT04769479 |
| Placebo | Other | Phase PHASE3 | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | WITHDRAWN | NCT04418024 |
| AG10 | Other | Phase PHASE3 | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | WITHDRAWN | NCT04418024 |
| Placebo | Other | Phase PHASE3 | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | WITHDRAWN | NCT04418024 |
| AG10 | Other | Phase PHASE3 | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | WITHDRAWN | NCT04418024 |
| Placebo Oral Tablet | Other | Phase PHASE1 | Amyloid Cardiomyopathy, Transthyretin-Related | COMPLETED | NCT03294707 |
| AG10 oral tablet | Other | Phase PHASE1 | Amyloid Cardiomyopathy, Transthyretin-Related | COMPLETED | NCT03294707 |
| Placebo Oral Tablet | Other | Phase PHASE1 | Amyloid Cardiomyopathy, Transthyretin-Related | COMPLETED | NCT03294707 |
| AG10 oral tablet | Other | Phase PHASE1 | Amyloid Cardiomyopathy, Transthyretin-Related | COMPLETED | NCT03294707 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia (ADH) | COMPLETED | NCT04581629 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia (ADH) | COMPLETED | NCT04581629 |
| 99mTc-pyrophosphate Scintigraphy | Other | Approved | Transthyretin Amyloidosis | RECRUITING | NCT05577819 |
| BBP-398 with nivolumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT05375084 |
| BBP-398 (Formerly known as IACS-15509) | Other | Phase PHASE1 | Tumor, Solid | TERMINATED | NCT04528836 |
| AI Toolkit for ATTR-CM Diagnosis | Other | Preclinical | Transthyretin (TTR) Amyloid Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT07062848 |
| Acoramidis (AG10) | Other | Phase PHASE3 | Amyloidosis in Transthyretin (TTR) | NOT_YET_RECRUITING | NCT07116473 |
| Acoramidis (AG10) | Other | Phase PHASE3 | Amyloidosis in Transthyretin (TTR) | NOT_YET_RECRUITING | NCT07116473 |
| Acoramidis (AG10) | Other | Phase PHASE3 | Amyloidosis in Transthyretin (TTR) | NOT_YET_RECRUITING | NCT07116473 |
| Infigratinib 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.128 mg/kg | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.064 mg/kg | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.032 mg/kg | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.016 mg/kg | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib | Other | Phase PHASE2 | Achondroplasia | ENROLLING_BY_INVITATION | NCT05145010 |
| Infigratinib | Other | Phase PHASE2 | Achondroplasia | ENROLLING_BY_INVITATION | NCT05145010 |
| infigratinib 0.25 mg/kg/day | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT06873035 |
| infigratinib 0.128 mg/kg/day | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT06873035 |
| infigratinib 0.25 mg/kg/day | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT06873035 |
| infigratinib 0.128 mg/kg/day | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT06873035 |
| ATTR-CM AI-ECG and AI-Echo Model | Other | Preclinical | ATTR Amyloidosis With Cardiomyopathy | NOT_YET_RECRUITING | NCT07398950 |
| Acoramidis (AG10) | Other | Phase PHASE3 | Amyloid Cardiomyopathy, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT04988386 |
| Acoramidis (AG10) | Other | Phase PHASE3 | Amyloid Cardiomyopathy, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT04988386 |
| Infigratinib | Other | Phase EARLY_PHASE1 | Glioma | TERMINATED | NCT04424966 |
| Infigratinib | Other | Phase EARLY_PHASE1 | Glioma | TERMINATED | NCT04424966 |
| Standard of Care | Other | Phase PHASE3 | Autosomal Dominant Hypocalcemia (ADH) | ACTIVE_NOT_RECRUITING | NCT05680818 |
| Encaleret | Other | Phase PHASE3 | Autosomal Dominant Hypocalcemia (ADH) | ACTIVE_NOT_RECRUITING | NCT05680818 |
| Standard of Care | Other | Phase PHASE3 | Autosomal Dominant Hypocalcemia (ADH) | ACTIVE_NOT_RECRUITING | NCT05680818 |
| Encaleret | Other | Phase PHASE3 | Autosomal Dominant Hypocalcemia (ADH) | ACTIVE_NOT_RECRUITING | NCT05680818 |
| Cardiac amyloidosis deep learning model | Other | Approved | Cardiac Amyloidosis | COMPLETED | NCT06469372 |
| Cardiac amyloidosis deep learning model | Other | Approved | Cardiac Amyloidosis | COMPLETED | NCT06469372 |
| ALXN2060 | Other | Phase PHASE3 | Symptomatic Transthyretin Amyloid Cardiomyopathy | COMPLETED | NCT04622046 |
| ALXN2060 | Other | Phase PHASE3 | Symptomatic Transthyretin Amyloid Cardiomyopathy | COMPLETED | NCT04622046 |
| ALXN2060 | Other | Phase PHASE3 | Symptomatic Transthyretin Amyloid Cardiomyopathy | COMPLETED | NCT04622046 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Infigratinib | Other | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT07393373 |
| Computed tomography (CT) | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Iopamidol | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Omnipaque 350 | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Tamoxifen | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Infigratinib | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Computed tomography (CT) | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Iopamidol | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Omnipaque 350 | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Tamoxifen | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Infigratinib | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| encaleret | Other | Phase PHASE2 | Post-Surgical Hypoparathyroidism | COMPLETED | NCT05735015 |
| Placebo Comparator 0.25 mg/kg/day | Other | Phase PHASE3 | Achondroplasia | COMPLETED | NCT06164951 |
| Infigratinib 0.25 mg/kg/day | Other | Phase PHASE3 | Achondroplasia | COMPLETED | NCT06164951 |
| Placebo Comparator 0.25 mg/kg/day | Other | Phase PHASE3 | Achondroplasia | COMPLETED | NCT06164951 |
| Infigratinib 0.25 mg/kg/day | Other | Phase PHASE3 | Achondroplasia | COMPLETED | NCT06164951 |
| Placebo Comparator 0.25 mg/kg/day | Other | Phase PHASE3 | Achondroplasia | COMPLETED | NCT06164951 |
| Infigratinib 0.25 mg/kg/day | Other | Phase PHASE3 | Achondroplasia | COMPLETED | NCT06164951 |
| Nab-paclitaxel | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Gemcitabine | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| NALIRIFOX | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| FOLFOX | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Cetuximab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Pemetrexed | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Platinum chemotherapy (cisplatin or carboplatin) | Drug | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Pembrolizumab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| BBO-11818 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Placebo oral tablet | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Acoramidis | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Placebo oral tablet | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Acoramidis | Other | Phase PHASE3 | Amyloidosis | RECRUITING | NCT06563895 |
| Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as a single dose of minitablets for oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as sprinkle capsules for daily oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Infigratinib is provided as a single dose of minitablets for oral administration | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT07169279 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| FOLFOX | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Ribociclib | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Fulvestrant | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Trastuzumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| BBO-10203 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| FOLFOX | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Ribociclib | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Fulvestrant | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Trastuzumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| BBO-10203 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| FOLFOX | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Ribociclib | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Fulvestrant | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Trastuzumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| BBO-10203 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-10203 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Pembrolizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| BBO-8520 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| infigratinib 0.25 mg/kg/day | DRUG | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT06873035 |
| infigratinib 0.128 mg/kg/day | DRUG | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT06873035 |
| Cardiac amyloidosis deep learning model | DEVICE | Approved | Cardiac Amyloidosis | COMPLETED | NCT06469372 |
| PTR-01 | DRUG | Phase PHASE2 | Recessive Dystrophic Epidermolysis Bullosa | COMPLETED | NCT05143190 |
| Iopamidol | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Omnipaque 350 | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Tamoxifen | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| BGJ398 (infigratinib) | DRUG | Phase PHASE2 | Advanced Cholangiocarcinoma | TERMINATED | NCT02150967 |
| BBP-671 | DRUG | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04836494 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04836494 |
| Cisplatin | DRUG | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| BGJ398 | DRUG | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| sotorasib | DRUG | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT05480865 |
| BBP-398 | DRUG | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT05480865 |
| BBP-398 (Formerly known as IACS-15509) | DRUG | Phase PHASE1 | Tumor, Solid | TERMINATED | NCT04528836 |
| Placebo Comparator 0.25 mg/kg/day | DRUG | Phase PHASE3 | Achondroplasia | ACTIVE_NOT_RECRUITING | NCT06164951 |
| Infigratinib 0.25 mg/kg/day | DRUG | Phase PHASE3 | Achondroplasia | ACTIVE_NOT_RECRUITING | NCT06164951 |
| Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration | DRUG | Phase PHASE2 | Achondroplasia | NOT_YET_RECRUITING | NCT07169279 |
| Infigratinib is provided as sprinkle capsules for daily oral administration | DRUG | Phase PHASE2 | Achondroplasia | NOT_YET_RECRUITING | NCT07169279 |
| Infigratinib is provided as a single dose of minitablets for oral administration | DRUG | Phase PHASE2 | Achondroplasia | NOT_YET_RECRUITING | NCT07169279 |
| Infigratinib 0.25 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.128 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.064 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.032 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.016 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib | DRUG | Phase PHASE1 | Bladder Transitional Cell Carcinoma | WITHDRAWN | NCT04972253 |
| ALXN2060 | DRUG | Phase PHASE3 | Symptomatic Transthyretin Amyloid Cardiomyopathy | COMPLETED | NCT04622046 |
| Encaleret | DRUG | Phase PHASE2 | Autosomal Dominant Hypocalcemia (ADH) | COMPLETED | NCT04581629 |
| encaleret | DRUG | Phase PHASE2 | Post-Surgical Hypoparathyroidism | COMPLETED | NCT05735015 |
| Nab-paclitaxel | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Gemcitabine | DRUG | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| NALIRIFOX | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Cetuximab | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Pemetrexed | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Platinum chemotherapy (cisplatin or carboplatin) | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| BBO-11818 | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Pembrolizumab | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| BBO-8520 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Bevacizumab | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| FOLFOX | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Ribociclib | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Fulvestrant | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Trastuzumab | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| BBO-10203 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
Total products: 314